MCL Literature Feed

Radiotherapy for localized orbital MCL achieves excellent long-term cancer-specific survival (83% at 15 years), supporting its use as a primary treatment, especially for elderly or frail patients.

This large, real-world analysis confirms a dismal prognosis (median OS 5.4 months) for MCL patients progressing after CAR-T, establishing a benchmark for future trials in this high-risk population.

This large real-world study confirms brexucabtagene autoleucel's high efficacy (91% ORR, 63% 1-yr PFS) in R/R MCL, supporting its standard-of-care role and suggesting earlier use improves outcomes.

This long-term Italian study confirms poor outcomes for allo-HSCT in relapsed/refractory MCL (27% 3-year PFS), with no survival benefit if not in complete remission pre-transplant.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

In a US community setting, real-world data shows MCL patients on zanubrutinib had significantly longer treatment duration and adherence compared to acalabrutinib and ibrutinib, suggesting better persistence.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

Korean real-world data confirms consolidative auto-SCT is effective, while in the relapsed setting, auto-SCT benefits chemosensitive patients and matched-donor allo-SCT is a viable option for refractory disease.

This Danish population-based study shows real-world ibrutinib outcomes (PFS 5.8 months) are inferior to clinical trials, with high-risk features and toxicity limiting efficacy, underscoring significant unmet needs.

The Endothelial Activation and Stress Index (EASIX) is a novel, independent prognostic biomarker in MCL, with high scores at diagnosis correlating with significantly shorter OS and PFS.

Polypharmacy independently predicts worse survival, hospitalization, and infection rates in lymphoid cancers, highlighting the critical need for medication reconciliation and management in the MCL population.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

A US claims analysis shows MCL treatment costs increase substantially with each line of therapy, driven by hospitalizations, underscoring the economic need for more effective, durable frontline regimens.

This large real-world analysis of elderly MCL patients shows improved first-line survival with modern therapies, but only modest survival gains after relapse, highlighting a critical unmet clinical need.

In a modern Canadian cohort, allogeneic transplant for relapsed/refractory MCL achieved a 5-year overall survival of 68.1%, confirming its ongoing relevance as a curative-intent therapy.

This real-world study from Colombia confirms the prognostic value of the MIPI score and the survival benefit of autologous stem cell transplant in a Latin American MCL cohort.

This study validates a method using electronic health records to define real-world progression in MCL, providing a scalable endpoint that correlates strongly with overall survival for evidence generation.

In high-risk, relapsed/refractory MCL, real-world data shows BTKi plus venetoclax is highly effective, with no added survival benefit from an anti-CD20 monoclonal antibody.

In a retrospective, mixed-histology study including four MCL patients, splenectomy plus chemotherapy improved survival for aggressive lymphomas presenting with primary splenic involvement, suggesting a potential therapeutic role.

In a prospective cohort of primary GI lymphomas including MCL, routine endoscopic surveillance significantly improved overall survival by detecting relapse early, supporting its role in post-treatment management.

In a small real-world study of 38 relapsed/refractory MCL patients, zanubrutinib was associated with fewer select adverse events like hypertension and hemorrhage compared to acalabrutinib.

In a real-world US analysis, relapsed/refractory MCL patients receiving CAR-T had longer treatment-free intervals and lower subsequent healthcare costs compared to standard therapies, supporting its earlier use.

Experienced nurses and advanced practice providers outline key considerations for implementing a successful outpatient lisocabtagene maraleucel CAR-T program, offering a practical framework for managing MCL patients.

Real-world data show BTKi refractoriness and poor in-vivo brexu-cel expansion predict worse survival, identifying high-risk patients for early relapse and highlighting CAR-T kinetics as a key biomarker.

A real-world Japanese study identified BTK inhibitor-based therapy and length of hospitalization as the main drivers of increased healthcare costs, providing crucial data for health economic planning.

A simulation model using 20 years of real-world data establishes a baseline for lifetime treatment trajectories, crucial for evaluating the cost-effectiveness of new targeted therapies in MCL.

This large Swedish real-world study on limited-stage MCL demonstrates that radiotherapy-containing frontline regimens are associated with excellent long-term outcomes, supporting a curative-intent, less-intensive approach for this rare subset.

This SEER database analysis confirms older age and advanced stage interact to worsen survival, while also identifying widowed marital status as an independent predictor of higher mortality in MCL.